Fig. 4.

Effect of si-DsbA-L on action of PPARγ agonist of improving insulin resistance

(a) Representative image of the immunoblots of cell samples (20 μg); (b) Relative expression of PI3K p110β quantified with β-actin; (c) Relative expression of total-AKT2 quantified with β-actin; (d) Relative expression of phospho-ERK1/2 quantified with total-ERK1/2; (e) Relative expression of DsbA-L quantified with β-actin. PPARγ: peroxisome proliferator-activated receptor γ; si-DsbA-L: small interfering RNA (siRNA) of disulfide-bond A oxidoreductase-like protein (DsbA-L); PI3K: phosphatidylinositol 3-kinase; AKT2: protein kinase B (PKB) β; ERK1/2: extracellular signal-regulated kinase 1/2; NC: negative control; RSG: rosiglitazone; t-AKT2: total-AKT2; p-ERK1/2: phospho-ERK1/2; t-ERK1/2: total-ERK1/2. Data are shown as mean±standard deviation (SD) (n=3). ^** P<0.01, ^*** P<0.001